U-CyTech Overview
- Year Founded
-
1999
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
U-CyTech General Information
Description
Developer of biomedical products designed to offer immunoassays for human, monkey, and rodent use. The company's products include cytokine enzyme-linked immunosorbent assays, T and B cell assays, and enzyme-linked Immuno spot systems which are designed for the ex vivo detection of individual protein-secreting cells, enabling clients to prepare efficient medicines for their biological research.
Contact Information
Website
www.ucytech.comCorporate Office
- Yalelaan 48
- 3584 CM Utrecht
- Netherlands
Corporate Office
- Yalelaan 48
- 3584 CM Utrecht
- Netherlands
U-CyTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Jan-1999 | Completed | Startup | |||
| 1. Spin-Off | 01-Jan-1999 | Completed | Startup |
U-CyTech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
U-CyTech Patents
U-CyTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040105843-A1 | Prevention of cellular damage in disease resulting from h/i-related blood flow resistance due to occlusion of blood vessels | Inactive | 03-Apr-2001 | 0000000000 | |
| US-20040136957-A1 | Administering a therapeutically relevant dose of ifn (interferon) type-i or a functional part, derivative and/or analogue thereof | Inactive | 03-Apr-2001 | 0000000000 | |
| DE-60129472-T2 | Treatment of hypoxya / ischaemia blood flow resistance with beta-interferon | Inactive | 03-Apr-2001 | 0000000000 | |
| EP-1377303-A2 | Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation | Inactive | 03-Apr-2001 | 0000000000 | |
| EP-1372702-A1 | Method of treatment of hypoxia/ischaemia related blood flow resistance | Active | 03-Apr-2001 | A61K38/212 |
U-CyTech Executive Team (2)
| Name | Title | Board Seat |
|---|---|---|
| Peter Van der Meide Ph.D | Founder, Owner & Co-Chief Executive Officer | |
| Nicole Van Besouw Ph.D | Chief Executive Officer |
U-CyTech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
U-CyTech Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Utrecht Holdings | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 |
U-CyTech FAQs
-
When was U-CyTech founded?
U-CyTech was founded in 1999.
-
Who is the founder of U-CyTech?
Peter Van der Meide Ph.D is the founder of U-CyTech.
-
Who is the CEO of U-CyTech?
Peter Van der Meide Ph.D and Nicole Van Besouw Ph.D are the CEOs of U-CyTech.
-
Where is U-CyTech headquartered?
U-CyTech is headquartered in Utrecht, Netherlands.
-
What is the size of U-CyTech?
U-CyTech has 7 total employees.
-
What industry is U-CyTech in?
U-CyTech’s primary industry is Biotechnology.
-
Is U-CyTech a private or public company?
U-CyTech is a Private company.
-
What is U-CyTech’s current revenue?
The current revenue for U-CyTech is 00000.
-
Who are U-CyTech’s investors?
Utrecht Holdings has invested in U-CyTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
